GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°
GLP-1 Receptor Agonist Market, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Geography
»óǰÄÚµå : 1672769
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,197,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,640,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,772,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ ¼¼°è ½ÃÀåÀº 2025³â¿¡ 281¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2032³â¿¡´Â 635¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2025-2032³â±îÁöÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 12.3%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 281¾ï 9,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£: 2025-2032³â CAGR 12.30% 2032³â ±Ý¾× ¿¹Ãø 635¾ï 4,000¸¸ ´Þ·¯
±×¸². GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
GLP-1 Receptor Agonist Market-IMG1

GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦´Â 2Çü ´ç´¢º´ Ä¡·á¸¦ À§ÇÑ Áß¿äÇÑ Ç×´ç´¢º´Á¦À¯Çüº°ÀÔ´Ï´Ù. À̵éÀº ³»ÀμºÀÇ ±Û·çÄ«°ï-À¯»ç ÆéƼµå-1(GLP-1)ÀÇ ÀÛ¿ëÀ» ¸ð¹æÇÑ °ÍÀ¸·Î, ½ÄÈÄ¿¡ ºÐºñµÇ´Â ÆéƼµå È£¸£¸óÀ̸ç, Æ÷µµ´ç ÀÇÁ¸ÀûÀ¸·Î Àν¶¸° ºÐºñ¸¦ ÀÚ±ØÇØ, ±Û·çÄ«°ï ºÐºñ¸¦ ¾ïÁ¦ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾àÁ¦´Â GLP-1 ¼ö¿ëü¿¡ °áÇÕÇÏ¿© Ȱ¼ºÈ­ÇÔÀ¸·Î½á ´ç´¢º´ ȯÀÚ¿¡¼­ Àν¶¸° ºÐºñ¸¦ À¯µµÇϰí, ±Û·çÄ«°ï ºÐºñ¸¦ ¾ïÁ¦Çϰí, ½Ä¿åÀ» ¾ïÁ¦ÇÏ¿© üÁß °¨¼Ò¸¦ ÃËÁøÇÕ´Ï´Ù. ´Ù¸¥ ¾àÈ¿ ºÐ·ù¿¡ ºñÇØ ¶Ù¾î³­ Ç÷´ç Á¶Àý È¿°ú¿Í ÀúÇ÷´ç À§ÇèÀÌ ³·¾Æ ¸Å·ÂÀûÀÎ ¼±ÅÃÀÌ µÇ¾î ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ÀÇ Å¹¿ùÇÑ Ä¡·á È¿°ú¿Í ÇÔ²² Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ºñ¸¸ Áõ°¡´Â 2Çü ´ç´¢º´ÀÇ À§ÇèÀ» Áõ°¡½ÃŰ¹Ç·Î º¸´Ù È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº °³¹ß ºñ¿ë°ú ¾ö°ÝÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. °³¼±µÈ Á¦Çü, À¯¿¬ÇÑ Åõ¿© ¿É¼Ç, ´õ ±ä ÀÛ¿ë ½Ã°£, ´ÙÁß ÀûÀÀÁõ µîÀ» Ư¡À¸·Î ÇÏ´Â ½ÅÁ¦Ç°ÀÇ Ãâ½Ã´Â ¼ºÀå ±âȸ¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. °³¹ß±â¾÷Àº ÀÓ»óÀûÀÀÀÇ È®´ë¿Í ȯÀÚÀÇ ÆíÀǼº Çâ»óÀ» À§ÇÑ °æ±¸Á¦ °³¹ßÀ» À§ÇØ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È Çà·ÄÀ» ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã¿Í ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ª¿¡ ÀÇÇÑ Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä °íÂûµµ Á¦°øÇÕ´Ï´Ù.

ÀÌ ¹®¼­¿¡¼­´Â ¼¼°è GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

º» Á¶»çÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷¿¡´Â Novo Nordisk A/S, Eli Lilly and Company, Sanofi µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° »ó½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°èÀÇ GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, ÆÇ¸ÅÀÚ, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ ½ÃÀå-Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ GLP-1 ¼ö¿ëü ÀÛµ¿¾à ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ GLP-1 ¼ö¿ëü ÀÛµ¿¾à ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ GLP-1 ¼ö¿ëü ÀÛµ¿¾à ½ÃÀå, ¿ëµµº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦8Àå ¼¼°èÀÇ GLP-1 ¼ö¿ëü ÀÛµ¿¾à ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦9Àå ¼¼°èÀÇ GLP-1 ¼ö¿ëü ÀÛµ¿¾à ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ºÐ¼®°¡ Ãßõ

Á¦12Àå Âü°í¹®Çå°ú Á¶»ç¹æ¹ý

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global GLP-1 Receptor Agonist Market is estimated to be valued at USD 28.19 Bn in 2025 and is expected to reach USD 63.54 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 28.19 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 12.30% 2032 Value Projection: USD 63.54 Bn
Figure. GLP-1 Receptor Agonist Market Share (%), By Region 2025
GLP-1 Receptor Agonist Market - IMG1

GLP-1 receptor agonists are an important class of anti-diabetic drugs for the treatment of type 2 diabetes. These mimic the effects of endogenous glucagon-like peptide-1 (GLP-1), a peptide hormone released after eating which stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner. By binding to and activating the GLP-1 receptor, these drugs induce insulin secretion, inhibit glucagon release, suppress appetite and promote weight loss in diabetic patients. Their superior glucose control efficacy and low risk of hypoglycemia as compared to other classes make them an attractive option, thus, driving the market growth.

Market Dynamics:

Global GLP-1 receptor agonist market growth is driven by growing prevalence of diabetes worldwide coupled with the superior therapeutic efficacy of GLP-1 receptor agonists. Rising levels of obesity can increase the risk of type 2 diabetes, thus, boosting demand for more effective medical treatments. However, high development costs and stringent regulatory approvals can hamper the market growth. New product launches featuring improved formulations, flexible dosing options, longer duration of action and multi-indication usage can offer growth opportunities. Manufacturers are investing in R&D to expand clinical indications and develop oral versions of these drugs to improve patient convenience.

Key Features of the Study:

This report provides in-depth analysis of the global GLP-1 receptor agonist market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global GLP-1 receptor agonist market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company and Sanofi

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global GLP-1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GLP-1 receptor agonist market

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global GLP-1 Receptor Agonist Market- Impact of Coronavirus (COVID-19) Pandemic

5. Global GLP-1 Receptor Agonist Market, By Drug Class, 2020 - 2032, (USD Bn)

6. Global GLP-1 Receptor Agonist Market, By Route of Administration, 2020 - 2032, (USD Bn)

7. Global GLP-1 Receptor Agonist Market, By Application, 2020 - 2032, (USD Bn)

8. Global GLP-1 Receptor Agonist Market, By Distribution Channel, 2020 - 2032, (USD Bn)

9. Global GLP-1 Receptor Agonist Market, By Region, 2020 - 2032, (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â